{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T13:58:04Z","timestamp":1785419884104,"version":"3.56.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T00:00:00Z","timestamp":1770681600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T00:00:00Z","timestamp":1773792000000},"content-version":"vor","delay-in-days":36,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"the Natural Science Foundation of Guangdong Province","award":["2025A1515012554"],"award-info":[{"award-number":["2025A1515012554"]}]},{"DOI":"10.13039\/501100002858","name":"the China Postdoctoral Science Foundation","doi-asserted-by":"crossref","award":["2022M721513 and 2024T170384"],"award-info":[{"award-number":["2022M721513 and 2024T170384"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"crossref"}]},{"name":"the President Foundation of Zhujiang Hospital, Southern Medical University","award":["yzjj2022qn06"],"award-info":[{"award-number":["yzjj2022qn06"]}]},{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81872059"],"award-info":[{"award-number":["81872059"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Cancer Innovative Research Program of Sun Yat-sen University Cancer Center","award":["CIRP-SYSUCC-PT13120101"],"award-info":[{"award-number":["CIRP-SYSUCC-PT13120101"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Precis. Onc."],"DOI":"10.1038\/s41698-026-01325-0","type":"journal-article","created":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T09:36:29Z","timestamp":1770716189000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Valproic acid reverses macrophage-mediated temozolomide resistance in macrophage-rich gliomas"],"prefix":"10.1038","volume":"10","author":[{"given":"Xiangrong","family":"Ni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wubing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengfei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuelu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minghao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Furong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengcheng","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangdong","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongping","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,10]]},"reference":[{"key":"1325_CR1","doi-asserted-by":"publisher","first-page":"vi1","DOI":"10.1093\/neuonc\/noae145","volume":"26","author":"M Price","year":"2024","unstructured":"Price, M. et al. CBTRUS Statistical Report: primary brain and other central nervous system tumors diagnosed in the United States in 2017-2021. Neuro Oncol. 26, vi1\u2013vi85 (2024).","journal-title":"Neuro Oncol."},{"key":"1325_CR2","doi-asserted-by":"publisher","first-page":"405","DOI":"10.2176\/nmc.ra.2018-0141","volume":"58","author":"S Jiapaer","year":"2018","unstructured":"Jiapaer, S., Furuta, T., Tanaka, S., Kitabayashi, T. & Nakada, M. Potential strategies overcoming the temozolomide resistance for glioblastoma. Neurol. Med. Chir. 58, 405\u2013421 (2018).","journal-title":"Neurol. Med. Chir."},{"key":"1325_CR3","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/j.cell.2019.06.024","volume":"178","author":"C Neftel","year":"2019","unstructured":"Neftel, C. et al. An integrative model of cellular states, plasticity, and genetics for glioblastoma. Cell 178, 835\u2013849 e821 (2019).","journal-title":"Cell"},{"key":"1325_CR4","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.ccell.2017.06.003","volume":"32","author":"Q Wang","year":"2017","unstructured":"Wang, Q. et al. Tumor evolution of glioma-intrinsic gene expression subtypes associates with immunological changes in the microenvironment. Cancer Cell 32, 42\u201356 e46 (2017).","journal-title":"Cancer Cell"},{"key":"1325_CR5","doi-asserted-by":"crossref","unstructured":"Li J. et al. PI3Kgamma inhibition suppresses microglia\/TAM accumulation in glioblastoma microenvironment to promote exceptional temozolomide response. Proc. Natl. Acad. Sci. USA 118, e2009290118 (2021),","DOI":"10.1073\/pnas.2009290118"},{"key":"1325_CR6","doi-asserted-by":"publisher","first-page":"98","DOI":"10.3389\/fonc.2012.00098","volume":"2","author":"M Nakada","year":"2012","unstructured":"Nakada, M., Furuta, T., Hayashi, Y., Minamoto, T. & Hamada, J. The strategy for enhancing temozolomide against malignant glioma. Front. Oncol. 2, 98 (2012).","journal-title":"Front. Oncol."},{"key":"1325_CR7","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1007\/s00280-020-04169-y","volume":"86","author":"XR Ni","year":"2020","unstructured":"Ni, X. R. et al. Combination of levetiracetam and IFN-alpha increased temozolomide efficacy in MGMT-positive glioma. Cancer Chemother. Pharm. 86, 773\u2013782 (2020).","journal-title":"Cancer Chemother. Pharm."},{"key":"1325_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-018-0626-8","volume":"18","author":"BM Scicchitano","year":"2018","unstructured":"Scicchitano, B. M. et al. Levetiracetam enhances the temozolomide effect on glioblastoma stem cell proliferation and apoptosis. Cancer Cell Int. 18, 136 (2018).","journal-title":"Cancer Cell Int."},{"key":"1325_CR9","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1093\/neuonc\/nop005","volume":"12","author":"J Fu","year":"2010","unstructured":"Fu, J., Shao, C. J., Chen, F. R., Ng, H. K. & Chen, Z. P. Autophagy induced by valproic acid is associated with oxidative stress in glioma cell lines. Neuro. Oncol. 12, 328\u2013340 (2010).","journal-title":"Neuro. Oncol."},{"key":"1325_CR10","doi-asserted-by":"publisher","first-page":"4150","DOI":"10.1158\/0008-5472.CAN-10-3498","volume":"71","author":"WP Roos","year":"2011","unstructured":"Roos, W. P. et al. Intrinsic anticancer drug resistance of malignant melanoma cells is abrogated by IFN-beta and valproic acid. Cancer Res. 71, 4150\u20134160 (2011).","journal-title":"Cancer Res."},{"key":"1325_CR11","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.canlet.2018.04.039","volume":"428","author":"J Basso","year":"2018","unstructured":"Basso, J., Miranda, A., Sousa, J., Pais, A. & Vitorino, C. Repurposing drugs for glioblastoma: from bench to bedside. Cancer Lett. 428, 173\u2013183 (2018).","journal-title":"Cancer Lett."},{"key":"1325_CR12","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1056\/NEJMoa043331","volume":"352","author":"ME Hegi","year":"2005","unstructured":"Hegi, M. E. et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N. Engl. J. Med. 352, 997\u20131003 (2005).","journal-title":"N. Engl. J. Med."},{"key":"1325_CR13","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1158\/2326-6066.CIR-21-0258","volume":"9","author":"Z Li","year":"2021","unstructured":"Li, Z. et al. Glioblastoma cell-derived lncRNA-containing exosomes induce microglia to produce complement C5, promoting chemotherapy resistance. Cancer Immunol. Res. 9, 1383\u20131399 (2021).","journal-title":"Cancer Immunol. Res."},{"key":"1325_CR14","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abl5165","volume":"8","author":"X Ni","year":"2022","unstructured":"Ni, X. et al. Interrogating glioma-M2 macrophage interactions identifies Gal-9\/Tim-3 as a viable target against PTEN-null glioblastoma. Sci. Adv. 8, eabl5165 (2022).","journal-title":"Sci. Adv."},{"key":"1325_CR15","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1016\/j.ccell.2019.05.003","volume":"35","author":"P Chen","year":"2019","unstructured":"Chen, P. et al. Symbiotic macrophage-glioma cell interactions reveal synthetic lethality in PTEN-null glioma. Cancer Cell 35, 868\u2013884 e866 (2019).","journal-title":"Cancer Cell"},{"key":"1325_CR16","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s12929-025-01126-w","volume":"32","author":"GA Lee","year":"2025","unstructured":"Lee, G. A. et al. IL-19 as a promising theranostic target to reprogram the glioblastoma immunosuppressive microenvironment. J. Biomed. Sci. 32, 34 (2025).","journal-title":"J. Biomed. Sci."},{"key":"1325_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.646384","volume":"12","author":"Z Cai","year":"2021","unstructured":"Cai, Z. et al. Valproic acid-like compounds enhance and prolong the radiotherapy effect on breast cancer by activating and maintaining anti-tumor immune function. Front. Immunol. 12, 646384 (2021).","journal-title":"Front. Immunol."},{"key":"1325_CR18","volume":"2022","author":"ZY Yang","year":"2022","unstructured":"Yang, Z. Y. & Wang, X. H. Valproic acid inhibits glioma and its mechanisms. J. Health. Eng. 2022, 4985781 (2022).","journal-title":"J. Health. Eng."},{"key":"1325_CR19","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.ccr.2009.12.020","volume":"17","author":"RG Verhaak","year":"2010","unstructured":"Verhaak, R. G. et al. Cancer genome atlas research n. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17, 98\u2013110 (2010).","journal-title":"Cancer Cell"},{"key":"1325_CR20","doi-asserted-by":"publisher","first-page":"592","DOI":"10.18632\/aging.101415","volume":"10","author":"D Jia","year":"2018","unstructured":"Jia, D. et al. Mining TCGA database for genes of prognostic value in glioblastoma microenvironment. Aging 10, 592\u2013605 (2018).","journal-title":"Aging"},{"key":"1325_CR21","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1038\/s43018-022-00475-x","volume":"3","author":"L Wang","year":"2022","unstructured":"Wang, L. et al. A single-cell atlas of glioblastoma evolution under therapy reveals cell-intrinsic and cell-extrinsic therapeutic targets. Nat. Cancer 3, 1534\u20131552 (2022).","journal-title":"Nat. Cancer"},{"key":"1325_CR22","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.3389\/fimmu.2018.01004","volume":"9","author":"Z Chen","year":"2018","unstructured":"Chen, Z. & Hambardzumyan, D. Immune microenvironment in glioblastoma subtypes. Front. Immunol. 9, 1004 (2018).","journal-title":"Front. Immunol."},{"key":"1325_CR23","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/nn.4185","volume":"19","author":"D Hambardzumyan","year":"2016","unstructured":"Hambardzumyan, D., Gutmann, D. H. & Kettenmann, H. The role of microglia and macrophages in glioma maintenance and progression. Nat. Neurosci. 19, 20\u201327 (2016).","journal-title":"Nat. Neurosci."},{"key":"1325_CR24","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1038\/s41593-020-00789-y","volume":"24","author":"AR Pombo Antunes","year":"2021","unstructured":"Pombo Antunes, A. R. et al. Single-cell profiling of myeloid cells in glioblastoma across species and disease stage reveals macrophage competition and specialization. Nat. Neurosci. 24, 595\u2013610 (2021).","journal-title":"Nat. Neurosci."},{"key":"1325_CR25","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1055\/s-0034-1385475","volume":"82","author":"W Froscher","year":"2014","unstructured":"Froscher, W., Kirschstein, T. & Rosche, J. Anticonvulsant therapy for brain tumour-related epilepsy. Fortschr. Neurol. Psychiatr. 82, 678\u2013690 (2014).","journal-title":"Fortschr. Neurol. Psychiatr."},{"key":"1325_CR26","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1093\/neuonc\/not057","volume":"15","author":"M Kerkhof","year":"2013","unstructured":"Kerkhof, M. et al. Effect of valproic acid on seizure control and on survival in patients with glioblastoma multiforme. Neuro. Oncol. 15, 961\u2013967 (2013).","journal-title":"Neuro. Oncol."},{"key":"1325_CR27","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1093\/neuonc\/noq044","volume":"12","author":"GC Bobustuc","year":"2010","unstructured":"Bobustuc, G. C. et al. Levetiracetam enhances p53-mediated MGMT inhibition and sensitizes glioblastoma cells to temozolomide. Neuro. Oncol. 12, 917\u2013927 (2010).","journal-title":"Neuro. Oncol."},{"key":"1325_CR28","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1007\/s10067-017-3922-0","volume":"37","author":"S Mohammadi","year":"2018","unstructured":"Mohammadi, S., Saghaeian-Jazi, M., Sedighi, S. & Memarian, A. Sodium valproate modulates immune response by alternative activation of monocyte-derived macrophages in systemic lupus erythematosus. Clin. Rheumatol. 37, 719\u2013727 (2018).","journal-title":"Clin. Rheumatol."},{"key":"1325_CR29","doi-asserted-by":"publisher","first-page":"2715","DOI":"10.3892\/or.2015.4232","volume":"34","author":"D Shen","year":"2015","unstructured":"Shen, D. et al. Interferon-alpha\/beta enhances temozolomide activity against MGMT-positive glioma stem-like cells. Oncol. Rep. 34, 2715\u20132721 (2015).","journal-title":"Oncol. Rep."},{"key":"1325_CR30","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1007\/s00280-007-0520-x","volume":"61","author":"A Natsume","year":"2008","unstructured":"Natsume, A. et al. A combination of IFN-beta and temozolomide in human glioma xenograft models: implication of p53-mediated MGMT downregulation. Cancer Chemother. Pharm. 61, 653\u2013659 (2008).","journal-title":"Cancer Chemother. Pharm."},{"key":"1325_CR31","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1073\/pnas.1614035114","volume":"114","author":"P Chen","year":"2017","unstructured":"Chen, P. et al. Gpr132 sensing of lactate mediates tumor-macrophage interplay to promote breast cancer metastasis. Proc. Natl. Acad. Sci. USA 114, 580\u2013585 (2017).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"1325_CR32","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/s11060-020-03527-3","volume":"148","author":"XR Ni","year":"2020","unstructured":"Ni, X. R. et al. Transferrin receptor 1 targeted optical imaging for identifying glioma margin in mouse models. J. Neurooncol. 148, 245\u2013258 (2020).","journal-title":"J. Neurooncol."},{"key":"1325_CR33","doi-asserted-by":"publisher","first-page":"3573","DOI":"10.1016\/j.cell.2021.04.048","volume":"184","author":"Y Hao","year":"2021","unstructured":"Hao, Y. et al. Integrated analysis of multimodal single-cell data. Cell 184, 3573\u20133587 e3529 (2021).","journal-title":"Cell"}],"container-title":["npj Precision Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01325-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01325-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01325-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T12:27:19Z","timestamp":1773836839000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01325-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,10]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1325"],"URL":"https:\/\/doi.org\/10.1038\/s41698-026-01325-0","relation":{},"ISSN":["2397-768X"],"issn-type":[{"value":"2397-768X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,10]]},"assertion":[{"value":"20 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"120"}}